Crossingbridge Advisors’s Aspire Biopharma ASBP Stock Holding History

Crossingbridge Advisors’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$107	Sell	20 -792	-98%	-$8.07K	﹤0.01%	152
2026 Q1	$7.42K	Buy	812 +792	+3,960%	+$42.2K	﹤0.01%	152
2025 Q4	$3.21K	Hold	20	–	–	﹤0.01%	102
2025 Q3	$7.42K	Buy	+20	New	+$10K	﹤0.01%	75
2024 Q3	–	Sell	-69	Closed	–	–	68
2024 Q2	$0	Buy	+69	New	+$940K	﹤0.01%	61

Other funds holding ASBP

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

VWM

Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Crossingbridge Advisors's ASBP Position: Q2 2026 in Review

Crossingbridge Advisors reduced its Aspire Biopharma (ASBP) stake by 98% in Q2 2026, selling an estimated $8.07K and leaving 20 shares worth $107. The position accounts for ﹤0.01% of the portfolio, ranked #152.

Crossingbridge Advisors first reported a position in ASBP in Q2 2024 and has held it in 5 quarters since. The position peaked at $7.42K in Q1 2026. 13 funds tracked by Wall St. Rank hold ASBP as of Q2 2026.

Crossingbridge Advisors held 20 shares of Aspire Biopharma worth $107 as of Q2 2026.
Crossingbridge Advisors sold 792 Aspire Biopharma shares in Q2 2026, an estimated $8.07K.
Aspire Biopharma made up ﹤0.01% of Crossingbridge Advisors's portfolio in Q2 2026, its #152 holding.
Crossingbridge Advisors first reported a position in Aspire Biopharma in Q2 2024 and has held it in 5 quarters since.
Crossingbridge Advisors's Aspire Biopharma position peaked at $7.42K in Q1 2026.
13 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2026.

Based on Crossingbridge Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.